Buy Call by ICICI Securities
ICICI Securities suggested a buy call on Sanofi India with a target price of Rs 7500. Read on to know more about the ICICI Securities research report.
Sanofi is among the fastest-growing companies in India in anti-diabetic therapy. Some of the important attributes of MNC pharma companies(Sanofi) including a strong growth track record and capability of new launches.
In Q2CY19, the stock’s revenue surged over 9% YoY to Rs 748 cr led by growth in power brands and new launches. EBITDA margins dropped 297 bps YoY to 21% and EBITDA de-grew 4% YoT to Rs 157.8 cr. While bottom-line shrank 2% YoY to Rs 97.4 cr on the back of a less-than-expected operational performance.
Disclaimer: The perspectives and investment tips are given in this section are the expert’s own and not that of the website or its management. We encourage clients to check with certified experts before taking any position in the stocks/shares mentioned.